Thomas Würdinger | Molecular Neuro-genetics Unit, Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical SchoolBoston, MassachusettsUSA7 aut. États-Unis Massachusetts
| 005C77
| Authors' Affiliations: General Clinical Lab/Mouse Cancer Clinic, The Netherlands Cancer Institute; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy; Utrecht University, Utrecht; Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania; Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; and Molecular Neurogenetics Unit, Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, MassachusettsAuthors' Affiliations: General Clinical Lab/Mouse Cancer Clinic, The Netherlands Cancer Institute; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy; Utrecht University, Utrecht; Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania; Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; and Molecular Neurogenetics Unit, Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, Massachusetts. États-Unis Massachusetts Authors' Affiliations: General Clinical Lab/Mouse Cancer Clinic, The Netherlands Cancer Institute; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy; Utrecht University, Utrecht; Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania; Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; and Molecular Neurogenetics Unit, Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, MassachusettsAuthors' Affiliations: General Clinical Lab/Mouse Cancer Clinic, The Netherlands Cancer Institute; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy; Utrecht University, Utrecht; Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania; Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; and Molecular Neurogenetics Unit, Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston
| 004411
| Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, Cancer Center Amsterdam, VU University Medical CenterAmsterdamNLD2 aut.7 aut. Pays-Bas AmsterdamHollande-Septentrionale
| 005C77
|
|
---|